Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal

Clinical Biochemistry

Volumn 44, Issue 2-3, 2011, Pages 237-244

  Shaker, Olfat G ^a   Hammam, Olfat A ^b   El Leithy, Tarek R ^c   El Ganzoury, Hossam ^c   Wishahi, Mohamed M ^c   Mikhailidis, Dimitri P ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^c Egypt   (Egypt)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

HTERT; Schistosomiasis; SQCC; TRAP; Urothelial carcinoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; DNA BINDING PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHISTOSOMAL SQUAMOUS CELL CARCINOMA; SCHISTOSOMAL UROTHELIAL CARCINOMA; SCHISTOSOMIASIS; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE; GENETICS; SQUAMOUS CELL CARCINOMA; URINARY BLADDER NEOPLASMS;

CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; DNA-BINDING PROTEINS; HUMANS; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 79151478819     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.028     Document Type: Article

References (60)

1. El Bolkainy M.N., Mokhtar N.M., Ghoneim M.A., Hussein M.H. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981, 48:2643-2648.
2. Rosin M.P., Anwar W.A., Ward A.J. Inflammation chromosomal instability and cancer; the schistosomiasis model. Cancer Res 1994, 54:1929s-1933s.
3. Kitinya J.N., Lauren P.A., Eshleman L.J., Paljarvi L., Tanaka K. The incidence of squamous and transitional cell carcinomas of the urinary bladder in Northern Tanzania in areas of high and low levels of endemic schistosoma haematobium infection. Tran R Trop Med Hyg 1986, 8:935-939.
4. Orlando C., Sestini R., Vona G., Pinzani P., Bianchi S., Giacca M., et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol 1996, 156:2089-2093.
5. Eissa S., Swellam M., Shehata H., El-Khouly I.M., El-Zayat T., El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 2010, 183(2):493-498.
6. Ellison V., Stillman B. Biochemical characterization of DNA damage checkpoint complexes: clamp loader and clamp complexes with specificity for 5′ recessed DNA. PLoS Biol 2003, 1:E33-E40.
7. Mondello C., Scovassi A. Telomeres, telomerase and apoptosis. Biochem Cell Biol 2004, 4:498-507.
8. Harley C. Telomere loss: mitotic clock or genetic time bomb. Mutat Res 1991, 256:271-282.
9. Artandi S.E., Attardi L.D. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005, 331:881-890.
10. Chen J.L., Greider C.W. Functional analysis of the pseudoknot structure in human telomerase RNA. Proc Natl Acad Sci USA 2005, 102:8080-8085.
11. Shay J.W. Meeting report: the role of telomeres and telomerase in cancer. Cancer Res 2005, 65:3513-3517.
12. Urquidi V., Tarin D., Goodison S. Role of telomerase in cell senescence and oncogenesis. Rev Méd 2000, 51:65-79.
13. Abdulamir A.S., Hafidh R.R., Kadhim H.S., Abubakar F. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res 2009, 28:27.
14. Sugino T., Yoshida K., Bolodeoku J., Tarin D., Goodison S. Telomerase activity and its inhibition in benign and malignant breast lesions. J Pathol 1997, 183:57-61.
15. Fan Y., Liu Z., Fang X., Ge Z., Ge N., Jia Y., et al. Differential expression of full-length telomerase reverse transcriptase MRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res 2005, 11:4331-4337.
16. Khalbuss W., Goodison S. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. J Cytol 2006, 3:18-25.
17. Lin Z., Kim H., Prk H., Kim Y., Cheon J., Kim I. The expression of Bcl2 and Bcl6 protein in normal and malignant transitional epithelium. Urol Res 2003, 31:272-275.
18. Yu D.S., Chang S.Y. The expression of oncoproteins in transitional cell carcinoma its correlation with pathological behavior, cell cycle and drug resistance. Urology 2002, 69:46-50.
19. Kamel D., Soini Y., Nuorva K., Khalifa A. P53 and c-erbB-2 expression in schistosomal urinary bladder carcinoma and schistosomal cystitis with premalignant lesions. Virchows Arch 1994, 424:349-354.
20. Chuadhary K.S., Lu Q.L., Abdel P.D. Expression of bcl-2 and p53 oncoproteins in schistosomiasis associated transitional and squamous cell carcinoma of urinary bladder. Br J Urol 1997, 79:84-87.
21. Spruck C.H., Ohneseit P.F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y.C., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 2000, 54:784-788.
22. Eissa S., Swellam M., Ali-Labib R., Mansour A., El-Malt O., Tash F.M. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J Urol 2007, 178(3 Pt 1):1068-1072.
23. Kubota Y., Petras R.E., Easley K.A., Bauer T.W., Tubbs R.R., Fazio V.W. Ki67 Determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992, 70:2602-2609.
24. McCormick D., Chong H., Hobbs C., Datta C., Hall P.A. Detection of the Ki-67 antigen in the fixed and wax embedded sections with the monoclonal antibody MIB 1. Histopathology 1993, 22:355-360.
25. Wu T.T., Chen J.H., Lee Y.H., Huang J.K. The role of BCL-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000, 163:758-760.
26. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I. World Health Organization classification of tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs 2004, IARC Press, Lyon.
27. Bradford M.M. A rapid and sensitive method for the microgram quantitation of protein utilizing the principle of protein dye binding. Anal Biochem 1976, 72:248-254.
28. Kim N.W., Piatyszek M., Prowse K., Harley C.B., West M.D., Ho P.D., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015. (Washington DC).
29. Iczkowski K.A., Pantazis C.G., McGregor D.H., Wu Y., Tawfik O.W. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma. Cancer 2002, 95:2487-2493.
30. Fullen D.R., Zhu W., Thomas D., Su L.D. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol 2005, 32:680-684.
31. Badr K.M., Nolen J.D., Derose P.B., Cohen C. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance BCL-2 HER2 L neu, and proliferation. Hum Pathol 2004, 35:184-189.
32. Soini Y., Turpeenniemi-Hujanen T., Kamel D., Autio-Harmainen H., Risteli J., Risteli L., et al. p53 immunohistochemistry in transitional ell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993, 68:1029-1035.
33. Yoshida K. Telomerase activity in gastrointestinal, bladder and breast carcinomas and their clinical applications. Nippon Rinsho 2004, 62:1368-1376.
34. Lee D., Yang S., Hong S., Chung B., Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998, 4:535-538.
35. Abd El Gawad I.A., Moussa H.S., Nasr M.I., El Gemae E.H., Masooud A.M., Ibrahim I.K., et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Cancer Inst 2005, 17:193-202.
36. Abdel-Salam I.M., Khaled H.M., Gaballah H.E., Mansour O.M., Kassem H.A., Metwaly A.M. Telomerase activity in bilharzial bladder cancer. Prognostic implications. Urol Oncol 2001, 6:149-153.
37. Hohaus S., Cavallo S., Bellacosa A. Telomerase activity in human laryngeal squamous cell carcinoma. Clin Cancer Res 1996, 2:1895-1900.
38. Hiyama E., Yokoyama T., Tatsumoto N. Telomerase activity in gastric cancer. Cancer Res 1995, 55:3258-3262.
39. Reddel R., Bryan T. Alternative lengthening of telomeres: dangerous road less traveled. Lancet 2003, 361:1840-1841.
40. Asaad N., Abd El-Wahed M., Mohamed A. Human telomerase reverse transcriptase (hTRET) gene expression in thyroid carcinoma: diagnostic and prognostic role. J Egypt Natl Cancer Inst 2006, 18:8-16.
41. Morsi M.I., Youssef A.I., Hassouna M.E., El-Sedafi A.S., Ghazal A.A., Zaher E.R. Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst 2006, 18:82-93.
42. Yoshida K., Sugino T., Tahara H. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997, 79:362-369.
43. Tahara H., Kuniyasu H., Yokozaki H. Telomerase activity in preneoplastic and neoplastic gastric & colorectal lesions. Clin Cancer Res 1995, 1:1245-1251.
44. Dettlaff-Pokora A., Matuszewski M., Schlichtholz B. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer. Cancer Lett 2005, 10(222):83-88.
45. Mavrommatis J., Mylona E., Gakiopoulou H., Stravodimos C., Zervas A., Giannopoulos A., et al. Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer. Anticancer Res 2005, 25:3109-3116.
46. Yan P., Benhattar J., Seelentag W., Stehle J.C., Bosman F.T. Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 2004, 121:391-397.
47. Nouri A.M., Darakhshan F., Cannell H., Paris A.M., Oliver R.T. The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer. Br J Urol 1996, 78:337-344.
48. Warren W., Biggs P.J., El-Baz M., et al. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumors from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumors. Carcinogenesis 1995, 16:1181-1189.
49. Abdel-Fattah R., Challen C., Griffiths T.R., Robinson M.C., Neal D.E., Lunec J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998, 77:2230-2238.
50. Fleshner N., Kapust L., Ezer D., Herschorn S., Klotz L. P53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000, 164:1177-1182.
51. Sarkis A.S., Dalbagni G., Gordon Cardo C. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993, 85:53-59.
52. Glick S.H., Howell L.P., White R.W. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996, 155:1754-1757.
53. Osman I., Scher Howard I., Zhang Z. Alteration affecting the p53 control pathway in bilharzial-related bladder cancer. Clin Cancer Res 1997, 3:536-544.
54. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M.L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature (London) 1992, 355:846-847.
55. Nakopoulu L., Vourlakou C., Zeveras A. The prevalence of Bcl2, p53 and Ki67 immunoreactivity in transitional cell bladder carcinoma and their clinicopathological correlates. Hum Pathol 1998, 29:146-154.
56. Tsujihashi H., Nakanishi A., Matsuda H. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1991, 145:846-851.
57. Stavropoulos N.E., Filiadis I., Loachim-Ehasazeris K., Tsimaris I., Kalogeras D., Stafanaki S., et al. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002, 22:3759-3764.
58. Frank I., Cheville J.C., Blute M.L., Lohse C.M., Karnes R.J., Weaver A.L., et al. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004, 101:1803-1808.
59. Kilicli-Camur N., Kilicaslan I., Gulluoglu M.G., Esen T., Uysal V. Impact of p53 and KI-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002, 52:463-469.
60. Wolf H.K., stober C., Hohenfellner R., Leissner J. Prognostic value of p53, p21 L WAF1, Bcl 2, Baxand Ki-67 immunoreactivity in PT1 G3 urothelial bladder carcinomas. Tumour Biol 2001, 22:328-336.